IntoCell

IntoCell develops the chemical components, linkers and payloads, that sit at the heart of antibody-drug conjugates (ADCs), a class of targeted cancer medicines that attach a potent cell-killing drug to an antibody so it can seek out and destroy cancer cells while sparing healthy tissue.

Its platform technologies are designed to be licensed or supplied to pharmaceutical and biotech companies developing ADC drug candidates. The company's core focus is its proprietary OHPAS linker platform, which it says can work with a broader range of drug molecules than the main competing linker technology. IntoCell is listed on KOSDAQ, South Korea's tech-oriented small-cap exchange.